Trial Profile
A clinical study assessing drug resistance in advanced gastrointestinal stromal tumor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Imatinib (Primary) ; Regorafenib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacodynamics
- 07 Mar 2022 New trial record
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium